|
|
Clinical relevance of non-neuronal auto-antibodies in patients with
anti-Hu or anti-Yo paraneoplastic diseases Lucinda Aguirre-Cruz, Jean-Luc Charuel,
Antoine F. Carpentier,
Baya Benyahia, Jean-Yves Delattre
and Lucile Musset
INSERM U 495 and Fédération de
Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière, Paris, France
[L.A.-C., B.B., J.-J.D.]. Laboratorio de Neuroinmunología,
Instituto Nacional de Neurología y Neurocirugía de México, Mexico
[L.A.-C.]. Laboratoire d immunochimie,
Hôpital de la Pitié-Salpêtrière, Paris, France [J.-L.C., L.M.]. Fédération de Neurologie Mazarin, Hôpital
de la Pitié-Salpêtrière, 47 bd de lhopital,
Paris, France [A.F.C.].
Correspondence to:
Antoine F. Carpentier,
Email: antoine.carpentier@psl.ap-hop-paris.fr, Phone: +33-0-1-42-16-03-83,
Fax: +33-0-1-44-23-81-85.
About half of the patients with paraneoplastic diseases develop an
immune response against neuronal antigens expressed by both the tumor
and the nervous system.
In 31 patients with anti-Hu antibodies and 19
patients with anti-Yo antibodies, we searched for the presence of
additional non-neuronal auto-antibodies and further studied whether
the presence of such auto-antibodies was correlated with a specific
oncological or neurological presentation.
Positive antinuclear
antibodies (ANA) were found at a titer of 1:40 or above in 48%
patients with anti-Hu antibodies, and in 37% patients with anti-Yo
antibodies.
Anti-cytoplasmic antibodies were also detected in 42%
patients with anti-Yo antibodies.
No specific correlation between the
presence of non-neuronal auto-antibodies and clinical characteristics
of the patients could be identified.
In particular, neither the type
of underlying cancer, the overall survival, the tumor response to
treatment, nor the neurological presentation were related to the
serological status.
Keywords: anti-cytoplasmic
antibody - anti-Hu antibody - anti-nuclear
antibody - anti-Yo antibody - cancer - paraneoplastic
syndrome
© Springer 2005
Source: http://www.springerlink.com/openurl.asp?genre=article&eissn=1573-7373&volume=71&issue=1&spage=39
DOI: http://dx.doi.org/10.1007/s11060-004-4536-3
|
